Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 19 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research

Catalyst Screening

Enzyme Catalysis

Medicinal Chemistry

Synthetic Chemistry

Analytical Chemistry

Full Time Equivalent(FTE)

Fee For Service(FFS)

Biology Research

Structural Biology

Cell Biology

Enzymology & Molecular Interactions

Antibody Discovery

Translational Medicine

Computational Biology & Molecular Modeling

Early Pharmacokinetics

Radiolabel ADME

02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients

Route Selection

Production Process Optimization

Clinical Sample Production

Impurity Traceability & Control

Generic Drug Process Study & Filing

Innovative Drug Process Study & Filing

Pharmaceutical preparation

Consistency Evaluation

Preformulation Study

Formulation Stability Study

GMP-based Clinical Sample Production & Packaging

Pilot-scale Preparation Testing

Laboratory-scale Preparation Testing

Preparation Quality Research

Formulation Technology Research

Analytical Method Development and Quality Control
CMC Filings
03 Preclinical Research
Pharmacology & Pharmacodynamics

Tumor Models

Digestive System Disease Models

Endocrine & Metabolic Disease Models

Inflammatory & Immune Diseases Models

Neural System Disease Models

Other Disease Models

Ocular Diseases Models

Cardiovascular Model

Drug Safety Evaluation

Pharmacology & Toxicology Study

Safety Pharmacology

Histopathological Study

Clinicopathological Study

Drug Safety Evaluation Basic Information

Toxicokinetics

DMPK

In Vitro ADME Assays

In Vivo Pharmacokinetic Assays

Bioanalysis

Macromolecular Drugs Bioanalysis

Micromolecular Drugs Bioanalysis

IND Filings
01 One-stop Integrated Services
Drug Discovery Platform
Pharmaceutical Research Platform
Preclinical Research Services
Chemical Drug Development
One-stop API Process R&D Department
Medicilon's CDMO Service Platform
Pharmaceutical Research CDMO Service Platform
Translational Medicine Platform
GLP-1 New Drug R&D Service
Botanical Drug Preclinical R&D Technology Platform
02 Innovative Drug Services
ADC R&D Service Platform
PROTAC R&D Service Platform
mRNA Vaccine Bioanalysis Platform
Non-clinical Research for Cellular Immunotherapies
Nucleic Acid Drug R&D Platform
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Platform
Metabolite Identification (MetID) Service Platform
Drug Forming Research Platform
Safety Assessment Lab of Process Chemistry
Flow Cytometry Technology Platform
SEND Format Conversion Platform
Process Department Solid Form Screening Platform
Green Chemistry Platform
Flow Sorting Platform
NanoString nCounter Detection Platform
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model Evaluation Platform
Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease Drug Efficacy Evaluation System
05 Advanced Preparation R&D
Inhalation drug R&D platform
Ophthalmic drug R&D platform
Skin Topical Preparation R&D
06 Drug Analysis
07 Public Services
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 50 Soldiers Field Place, Boston, MA 02135 (America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2023-07-27Medicilon Events
The Medicilon DMPK team was praised again, and Dr. Yan Feng, CEO of Leading Tac Pharma, came to present the award
Dr. Yan Feng, CEO of Leading Tac Pharma, came to present the award the Medicilon DMPK team the "Best Partner Award" to express their gratitude and recognition.
Learn more
2023-07-27Medicilon Events
Fudan University, School of Management "Science and Technology Entrepreneur Camp" entered Medicilon: "Hardcore Technology" as the background color, Adding "luster" to new drug research and development
On July 14, Professor Xiongwen Lu, Dean of the School of Management of Fudan University, led the professor group of Fudan School of Management and the students of the fifth phase of the Fudan Science and Technology Entrepreneur Camp into the Zhangjiang Park of Shanghai Medicilon Inc. (Medicilon) to conduct a site visit.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CAREERS
Talent Development
Employee Activities
Campus Recruitment
Social Recruitment
Campus Recruitment
Campus Recruitment
Social Recruitment
Social Recruitment
Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon FTE services & FFS services - flexible and efficient cooperation model| Medicilon appeared at the 25th SAPA-NE Annual Conference
Sep 22,2021
Medicilon is Listed on the Top Chinese R&D CRO Enterprises in 2021
Shanghai Medicilon Inc. (Medicilon) was invited to participate in this event and was awarded the Top Chinese R&D CRO Enterprises in 2021 .
More
Medicilon is Listed on the Top Chinese R&D CRO Enterprises in 2021
Sep 22,2021
Medicilon attended the 21st China International Fair for Investment and Trade
Medicilon attended the 21st China International Fair for Investment and Trade and signed a strategic collaboration agreement with Xiamen Biotime. The 21st China International Fair
More
Medicilon attended the 21st China International Fair for Investment and Trade
Sep 22,2021
Targeting IL-23, Medicilon Assists the Development of a Variety of New Drugs for Psoriasis
IL-23 is mainly produced by activated dendritic cells, macrophages and monocytes. It is a new member of the IL-12 heterodimeric cytokine family.
More
Targeting IL-23, Medicilon Assists the Development of a Variety of New Drugs for Psoriasis
Sep 15,2021
The 19th Annual San Diego BioPharma Conference
Agenda 9:00 am Welcome and Opening Remarks Tao Wu, PhD, President, SABPA Yi Liu, PhD, Chair, BioPharmaCommittee, SABPA; CEO, Kumqat Biosciences 9:15 am Floyd Romesberg,
More
The 19th Annual San Diego BioPharma Conference
Sep 13,2021
Medicilon won the "Science and Technology Innovation Service Demonstration Case" Award
Shanghai Medicilon Inc. (Medicilon) "Internet + One-Stop Preclinical R&D Service Platform" was awarded the "Science and Technology Innovation Service Demonstration Case” award.
More
Medicilon won the "Science and Technology Innovation Service Demonstration Case" Award
Sep 13,2021
Medicilon appoints Dr. Hong Wan as Vice President of DMPK and Bioanalysis Department
Recently, Shanghai Medicilon Inc. (stock code: 688202.SH) (Medicilon) announced the appointment of Dr. Hong Wan as Vice President of DMPK and Bioanalysis Department. Dr. Hong
More
Medicilon appoints Dr. Hong Wan as Vice President of DMPK and Bioanalysis Department
Aug 19,2021
Medicilon Drug Discovery--Opening the Door of Innovative Drugs with Science and Professionalism
More
Medicilon Drug Discovery--Opening the Door of Innovative Drugs with Science and Professionalism
Aug 16,2021
Kumquat Biosciences and Eli Lilly have reached a partnership to jointly develop tumor immune small molecule drugs
Recently, Loxo Oncology, a research and development group of Eli Lilly, and Kumquat Biosciences (Kumquat) announced that the two parties have reached an exclusive collaboration
More
Kumquat Biosciences and Eli Lilly have reached a partnership to jointly develop tumor immune small molecule drugs
Aug 16,2021
Qing Ruan, Deputy Director of Shanghai Municipal Development and Reform Commission, and his team examined Medicilon
On August 4, 2021, Mr. Qing Ruan, Deputy Director of Shanghai Municipal Development and Reform Commission, and his team visited Shanghai Medicilon Inc. (Medicilon) at
More
Qing Ruan, Deputy Director of Shanghai Municipal Development and Reform Commission, and his team examined Medicilon
Aug 13,2021
Medicilon assists Ringene Biopharma 's SHP2 allosteric inhibitor RG001 tablet to be approved for clinical use
Recently, Shanghai Ringene Biopharma (Ringene) announced that the company's self-developed anti-tumor class I new drug SHP2 allosteric inhibitor RG001 tablet has been approved for clinical
More
Medicilon assists Ringene Biopharma 's SHP2 allosteric inhibitor RG001 tablet to be approved for clinical use
Aug 06,2021
Medicilon assists Leado Pharma to obtain clinical approval for small molecule inhibitor LDS tablets targeting transient receptor potential channels
On July 28, 2021, the Class 1 innovative drug LDS tablets developed by Shanghai Leado Pharma Technology Co., Ltd. (Leado Pharma) received the National Medical
More
Medicilon assists Leado Pharma to obtain clinical approval for small molecule inhibitor LDS tablets targeting transient receptor potential channels
Jul 16,2021
[Medicilon Assist] QHRD110 Capsules, a Class 1 Anti-cancer Drug Targeted by Qianhong, was Approved for Clinical Trials
Recently, Changzhou Qianhong Bio-Pharma targeted anti-cancer Class 1 new drug QHRD110 capsules was approved for clinical trials.
More
[Medicilon Assist] QHRD110 Capsules, a Class 1 Anti-cancer Drug Targeted by Qianhong, was Approved for Clinical Trials
Stock Code
688202

Global

Address: 50 Soldiers Field Place, Boston, MA 02135 (America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 24, Seochojungang-ro 8-gril, Seocho-gu, Seoul, 06643 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->